Exagen Inc. (XGN) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

17/25

Growth 5 Margin 4 Expansion 4 Platform 2 Financial 2

latest quarter score

Earnings Reports

17
Exagen (XGN) Q2 2026: ASP Climbs 4% as Revenue Cycle Initiatives Drive Near Break-Even
August 04, 2026
16
Exagen (XGN) Q1 2026: Ordering Clinicians Rise 15%, Underscoring Channel Penetration Momentum
May 11, 2026
13
XGN Q4 2025: Pharma Services Backlog Tops $4M, Raising Visibility on Diversification Strategy
March 10, 2026
18
Exagen (XGN) Q3 2025: ASP Rises 9% as Volume and Biomarker Innovation Drive Record Revenue
November 04, 2025
18
Exeget (XGN) Q2 2025: Per-Territory Revenue Jumps 50% as Commercial Execution Accelerates
August 05, 2025
19
Exeget (XGN) Q2 2025: Per-Territory Revenue Climbs 50%, Commercial Leverage Accelerates
August 05, 2025
17
Exagen Inc. (XGN) Q1 2025: 8% Revenue Growth Fueled by ASP Expansion and Volume Gains
May 05, 2025
16
Exagen Inc. (XGN) Q4 2024: $90 ASP Lift from New Biomarkers Sets Stage for Profitable Growth
March 11, 2025

Browse all companies